Display options
Cite
Dow DJ, McMahon AD, Gray IC, et al. CCR2 and coronary artery disease: a woscops substudy. BMC Res Notes. 2010;3:31doi: 10.1186/1756-0500-3-31.
Dow, D. J., McMahon, A. D., Gray, I. C., Packard, C. J., & Groot, P. H. (2010). CCR2 and coronary artery disease: a woscops substudy. BMC research notes, 331. https://doi.org/10.1186/1756-0500-3-31
Dow, David J, et al. "CCR2 and coronary artery disease: a woscops substudy." BMC research notes vol. 3 (2010): 31. doi: https://doi.org/10.1186/1756-0500-3-31
Dow DJ, McMahon AD, Gray IC, Packard CJ, Groot PH. CCR2 and coronary artery disease: a woscops substudy. BMC Res Notes. 2010 Feb 02;3:31. doi: 10.1186/1756-0500-3-31. PMID: 20181074; PMCID: PMC2829582.
Copy Download .nbib Format: NLM
Share it on

BMC Res Notes. 2010 Feb 02;3:31. doi: 10.1186/1756-0500-3-31.

CCR2 and coronary artery disease: a woscops substudy.

BMC research notes

David J Dow, Alex D McMahon, Ian C Gray, Chris J Packard, Pieter He Groot

Affiliations

  1. GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UK. [email protected]

PMID: 20181074 PMCID: PMC2829582 DOI: 10.1186/1756-0500-3-31

Abstract

BACKGROUND: Several lines of evidence support a role for CCL2 (monocyte chemotactic protein-1) and its receptor CCR2 in the development of atherosclerosis. The aim of the present study was to determine the association of the CCR2 Val64Ile polymorphism with the development of coronary artery disease in the WOSCOPS study sample set.

FINDINGS: A total of 443 cases and 1003 controls from the West of Scotland Coronary Prevention Study (WOSCOPS) were genotyped for the Val64Ile polymorphism in the CCR2 gene. Genotype frequencies were compared between cases and controls. The CCR2 Val64Ile polymorphism was found not to be associated with coronary events in this study population (odds ratio 1.15, 95% CI 0.82-1.61, p = 0.41).

CONCLUSIONS: This case-control study does not support an association of the CCR2 Val64Ile polymorphism with coronary artery disease in the WOSCOPS sample set and does not confirm a possible protective role for CCR2 Val64Ile in the development of coronary artery disease.

References

  1. Trends Pharmacol Sci. 1994 May;15(5):159-65 - PubMed
  2. Science. 1997 Aug 15;277(5328):959-65 - PubMed
  3. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1518-25 - PubMed
  4. N Engl J Med. 1999 Jan 14;340(2):115-26 - PubMed
  5. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):447-53 - PubMed
  6. Atherosclerosis. 2006 Oct;188(2):341-6 - PubMed
  7. Eur Heart J. 2004 Aug;25(16):1378-81 - PubMed
  8. Atherosclerosis. 2001 Sep;158(1):233-9 - PubMed
  9. J Clin Invest. 2007 Jan;117(1):185-94 - PubMed
  10. Am J Cardiol. 1995 Sep 1;76(7):485-91 - PubMed
  11. Curr Opin Lipidol. 2004 Apr;15(2):145-9 - PubMed
  12. Thromb Res. 2007;119(1):63-71 - PubMed
  13. Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1412-8 - PubMed
  14. Circulation. 1995 Oct 15;92(8):2157-62 - PubMed
  15. Mol Cell. 1998 Aug;2(2):275-81 - PubMed
  16. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12053-8 - PubMed
  17. J Clin Invest. 1991 Oct;88(4):1121-7 - PubMed
  18. Genes Immun. 2001 Jun;2(4):191-5 - PubMed
  19. Atherosclerosis. 1999 Mar;143(1):205-11 - PubMed
  20. J Mol Med (Berl). 2003 Jun;81(6):363-7 - PubMed
  21. J Clin Invest. 1997 Nov 15;100(10):2552-61 - PubMed
  22. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2752-6 - PubMed
  23. J Mol Med (Berl). 2003 Jan;81(1):4-19 - PubMed
  24. Trends Cardiovasc Med. 2003 Nov;13(8):309-16 - PubMed
  25. Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1924-8 - PubMed
  26. Methods Mol Biol. 2006;335:215-40 - PubMed

Publication Types